PFE
PFIZER INC
NYSE: PFE · New York, NY · Healthcare
$28.45-0.36 (-1.25%)Closed
Market Cap$162.16B
Cash$976.0Mmost recent
Runwayprofitable
P/E (TTM)20.9EPS $1.36
52-Wk Range$22.05 – $29.02
Avg Volume48.7M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$28.45+14.3%
Pipeline

Drug candidates sponsored by PFIZER · ClinicalTrials.gov

92 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4artesunate sachets
Healthy Volunteers
Completed
2009-06past
1
Phase 4Anidulafungin
Candidemia+1 more
Completed
2009-10past
1
Phase 4temsirolimus
Non-Hodgkin's Lymphoma
Completed
2015-11past
1
Phase 4Etanercept
Psoriasis+1 more
Completed
2020-10-01past
2
Phase 4pneumococcus conjugate vaccine
Vaccines, Pneumococcal Conjugate Vaccine
Completed—1
Phase 3SPM 907
Overactive Bladder Syndrome
Completed
2005-02past
1
Phase 3VENLAFAXINE
Panic Disorders
Completed
2006-04past
1
Phase 3torcetrapib/atorvastatin
Coronary Disease+1 more
Terminated
2007-06past
1
Phase 3Inhaled insulin (Exubera)
Diabetes Mellitus, Type 1
Terminated
2007-10past
1
Phase 3Desvenlafaxine Succinate Sustained-Release (DVS SR)
Diabetic Neuropathy, Painful
Terminated
2009-01past
1
Phase 3Xiapex
Dupuytren's Contracture
Completed
2012-10past
1
Phase 3Azithromycin plus chloroquine
Asymptomatic Parasitemia In Pregnancy
Terminated
2013-06past
1
Phase 3pegaptanib sodium
Anti- VGF Inhibitor+3 more
Completed
2014-02past
2
Phase 3Tigecycline
Community Acquired Bacterial Pneumonia+1 more
Withdrawn
2014-05past
1
Phase 3Meningococcal vaccine GSK134612
Infections, Meningococcal
Completed
2018-02past
1
Phase 3Placebo
Seizures+6 more
Completed
2020-04-08past
3
Phase 2PF-06651600 Induction Dose
Alopecia Areata
Completed
2020-12-31past
1
Phase 3Clostridium difficile vaccine
Clostridium Difficile Infection
Completed
2021-12-21past
1
Phase 3Chemotherapy + avelumab followed by avelumab + talazoparib
Ovarian Cancer
Terminated
2021-12-22past
1
Phase 3RSVpreF
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Completed
2024-03-18past
1
Phase 3Inclacumab
Sickle Cell Disease+2 more
Terminated
2025-11-07past
2
Phase 3Tilrekimig
Atopic Dermatitis
Recruiting
2028-03-10
1
Phase 2Etrasimod
Crohn's Disease+1 more
Active, not recruiting
2029-06-19
2
Phase 2Osivelotor
Sickle Cell Disease
Recruiting
2030-12-30
1
Phase 3Unnamed
Growth Hormone Deficiency
Completed—1
Phase 3varenicline
Smoking Cessation
Completed—1
Phase 2Meningococcal C
Meningitis, Meningococcal
Completed
1998-04past
1
Phase 2tofimilast
Pulmonary Disease, Chronic Obstructive
Completed
2005-07past
1
Phase 2Methotrexate plus ERB-041 for 12 weeks
Rheumatoid Arthritis
Completed
2006-10-19past
1
Phase 2AN2728
Psoriasis
Completed
2008-03past
1
Phase 2UK-432,097
Pulmonary Disease, Chronic Obstructive
Terminated
2008-07past
1
Phase 2carboplatin
Non-small Cell Lung Cancer
Completed
2009-03past
1
Phase 2Apixaban
Atrial Fibrillation
Completed
2009-09past
1
Phase 2Sunitinib Malate Continuous Daily Dosing
Carcinoma, Renal Cell
Completed
2010-06past
1
Phase 2NXL104/ceftazidime
Complicated Urinary Tract Infection
Completed
2010-06past
1
Phase 1axitinib
Carcinoma, Non-Small Cell Lung
Completed
2011-03past
1
Phase 2CP-601,927
Major Depressive Disorder
Terminated
2011-09-12past
1
Phase 2Ceftaroline Fosamil
Late-onset Sepsis
Terminated
2017-12-26past
1
Phase 2PF-05221304 Monotherapy
Non-Alcoholic Fatty Liver Disease (NAFLD)
Completed
2019-09-09past
1
Phase 2capravirine
HIV Infections
Completed—1
Phase 2Inhaled insulin
Diabetes Mellitus, Type 2
Completed—1
Phase 1AG-013,958
Age-Related Macular Degeneration
Terminated—1
Phase 2Bazedoxifene
Postmenopausal Osteoporosis
Completed—1
Phase 2CP-547,632
Ovarian Neoplasms+2 more
Completed—1
Phase 1HCV-796
Healthy
Completed
2006-11past
1
Phase 1IMA-026
Healthy
Completed
2008-07past
1
Phase 1SU011248; Capecitabine
Solid Tumors+2 more
Completed
2008-07past
1
Phase 1Premarin
Postmenopause
Completed
2008-10past
1
Phase 1SAM-531
Alzheimer Disease
Completed
2009-02past
2
Phase 1varenicline free base patch
Smoking Cessation
Completed
2009-12past
1
Phase 1PF-03526299
Asthma
Completed
2009-12past
1
Phase 1azithromycin (AZ) microsphere
Malaria Prophylaxis
Completed
2010-06past
1
Phase 1Treatment A
Pharmacokinetics
Completed
2011-01past
1
Phase 1PF-03715455
Chronic Obstructive Pulmonary Disease (COPD)
Completed
2011-12past
1
Phase 1PF-05175157
Diabetes Mellitus, Type 2
Completed
2012-05past
1
Phase 1tofacitinib 10 mg
Healthy
Completed
2012-07past
1
Phase 1PF-06412562
Parkinson's Disease
Completed
2014-08past
1
Phase 120 mg PF-02545920
Healthy
Completed
2014-09past
1
Phase 1PF-06372865
Healthy
Withdrawn
2015-08past
1
Phase 1Intravenous infusions of Xyntha
Hemophilia A
Completed
2015-08past
1
Phase 1PF-06463922
Healthy
Completed
2016-04past
1
Phase 1Unnamed
Healthy Subjects
Completed
2016-05past
1
Phase 1PF-04965842
Healthy Volunteers
Completed
2018-10-01past
1
Phase 1PF-05221304 Formulation A
Healthy
Completed
2019-05-08past
1
Phase 1PF-06651600
Healthy Females+1 more
Completed
2019-10-11past
2
Phase 1Lorlatinib 50 mg
Adult+3 more
Completed
2019-12-09past
1
Phase 14 mg Fesoterodine ER tablet from Zwickau
Neurogenic Detrusor Overactivity
Completed
2020-11-12past
1
Phase 1PF-06650833
Healthy
Completed
2021-12-16past
1
Phase 1Formulation A (PF-07081532 20 mg plus 60 mg)
Overweight+1 more
Completed
2023-03-14past
1
Phase 1PF-06863135 monotherapy IV or SC
Multiple Myeloma
Completed
2024-01-19past
1
Phase 1PF-07940367
Healthy
Completed
2024-05-07past
1
Phase 1PF-07899895
Healthy
Terminated
2025-10-24past
1
Phase 1PF-07934040
Carcinoma, Pancreatic Ductal+2 more
Active, not recruiting
2026-10-09
1
Phase 17-valent pneumococcal conjugate vaccine
Pneumococcal Infections
Completed—1
Phase 1HIV-1 gag DNA (formulated with bupivacaine)
HIV Infections
Terminated—1
Phase 1Lecozotan SR
Alzheimer Disease
Completed—1
Phase 1ERB-041
Healthy+1 more
Completed—1
N/ASU011248
Neoplasms
Completed
2011-12past
1
N/AVoriconazole
Scedosporium Infection
Completed
2012-05past
1
N/ALinezolid
Complicated Skin and Structure Infection+1 more
Completed
2012-05past
1
N/AAromasin
Invasive Early Breast Cancer
Terminated
2012-12past
1
N/ACrizotinib (Xalkori)
Non-small Cell Lung Cancer
Completed
2018-03-16past
1
N/Apalbociclib
Metastatic Breast Cancer
Completed
2022-11-30past
1
N/AUnnamed
Breast Cancer+1 more
Completed
2023-05-02past
1
N/AUnnamed
Achondroplasia
Completed
2023-05-16past
1
N/AUnnamed
Transthyretin Amyloid Cardiomyopathy+1 more
Terminated
2023-06-02past
1
N/AEnco+bini
Metastatic Melanoma
Completed
2023-12-31past
1
N/AVaccination
SARS-CoV-2+1 more
Completed
2024-07-31past
1
N/AUnnamed
Respiratory Syncytial Virus (RSV)
Active, not recruiting
2026-09-30
1
N/Adarolutamide plus androgen deprivation therapy
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Not yet recruiting
2026-11-15
1
N/AUnnamed
HER2-positive Locally Advanced Unresectable+1 more
Not yet recruiting
2029-05-01
1
N/AUnnamed
Pain+2 more
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for PFE. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.